Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)

Acquired resistance mutations in EGFR-mutant NSCLC have a low observed frequency among molecularly-profiled tumors, possibly due to infrequent re-testing of resistant tumors. While T790M and C797S mutations are well-described, we also observed a significant number of L718 mutations in osimertinib-treated patients. These data support NGS evaluation of NSCLC that has become resistant to EGFR TKIs.